Get the Stockscreener App
1.12
5.08%
-0.06
After Hours:
1.14
0.02
+1.79%
Scynexis Inc stock is traded at $1.12, with a volume of 685.26K.
It is down -5.08% in the last 24 hours and up +30.25% over the past month.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
See More
Previous Close:
$1.18
Open:
$1.21
24h Volume:
685.26K
Relative Volume:
3.66
Market Cap:
$46.96M
Revenue:
$3.26M
Net Income/Loss:
$-19.52M
P/E Ratio:
-2.80
EPS:
-0.4
Net Cash Flow:
$-24.10M
1W Performance:
+25.84%
1M Performance:
+30.25%
6M Performance:
+22.79%
1Y Performance:
-16.42%
1-Day Range:
$1.08
$1.31
1-Week Range:
$0.89
$1.31
52-Week Range:
$0.66
$1.66
Scynexis Inc Stock (SCYX) Company Profile
Name
Scynexis Inc
Sector
Phone
201-884-5485
Address
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Compare SCYX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
1.12 | 43.60M | 3.26M | -19.52M | -24.10M | -0.40 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-21 | Initiated | Guggenheim | Buy |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-18 | Upgrade | Needham | Hold → Buy |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-10-17 | Initiated | ROTH Capital | Buy |
| May-09-17 | Downgrade | Needham | Buy → Hold |
| Mar-03-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-20-16 | Initiated | H.C. Wainwright | Buy |
| Oct-07-16 | Upgrade | WBB Securities | Buy → Strong Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Aug-17-16 | Initiated | Guggenheim | Buy |
| Aug-09-16 | Reiterated | Needham | Buy |
| Aug-09-16 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Mar-28-16 | Initiated | Brean Capital | Buy |
| Dec-29-15 | Initiated | WBB Securities | Speculative Buy |
| Nov-16-15 | Reiterated | RBC Capital Mkts | Outperform |
| Jun-10-15 | Initiated | Needham | Buy |
| May-29-14 | Initiated | Canaccord Genuity | Buy |
| May-29-14 | Initiated | RBC Capital Mkts | Outperform |
View All
Scynexis Inc Stock (SCYX) Latest News
What earnings revisions data tells us about SCYNEXIS Inc.Quarterly Trade Review & Capital Efficient Trading Techniques - Newser
Chart based exit strategy for SCYNEXIS Inc.2025 Key Lessons & Long-Term Capital Growth Strategies - Newser
How to integrate SCYNEXIS Inc. into portfolio analysis tools2025 Investor Takeaways & Technical Buy Zone Confirmation - Newser
Does SCYNEXIS Inc. show high probability of reboundMarket Performance Summary & Growth Focused Entry Reports - Newser
Ranking SCYNEXIS Inc. among high performing stocks via toolsTrade Volume Report & Free Weekly Chart Analysis and Trade Guides - Newser
Visual trend scoring systems applied to SCYNEXIS Inc.July 2025 Big Picture & Low Drawdown Investment Ideas - Newser
ranking scynexis inc. among high performing stocks via tools2025 Fundamental Recap & Weekly High Return Forecasts - Newser
Using fundamentals and technicals on SCYNEXIS Inc.Bull Run & Technical Pattern Based Signals - Newser
Applying Elliott Wave Theory to SCYNEXIS Inc.2025 Key Lessons & Weekly Breakout Stock Alerts - Newser
Will SCYNEXIS Inc. outperform the market2025 Trading Recap & Consistent Growth Stock Picks - Newser
Understanding SCYNEXIS Inc.’s price movementTrade Risk Assessment & Low Volatility Stock Recommendations - Newser
Heatmap analysis for SCYNEXIS Inc. and competitors2025 Stock Rankings & Long-Term Safe Investment Plans - Newser
SCYNEXIS Inc. stock trend forecastWeekly Trade Review & Entry Point Confirmation Signals - Newser
What’s next for SCYNEXIS Inc. stock priceJuly 2025 Spike Watch & Long-Term Safe Return Strategies - Newser
Quantitative breakdown of SCYNEXIS Inc. recent moveStop Loss & Short-Term High Return Strategies - Newser
Backtesting results for SCYNEXIS Inc. trading strategiesMarket Performance Summary & Reliable Volume Spike Trade Alerts - Newser
SCYNEXIS Inc. stock chart pattern explainedMarket Weekly Review & Weekly Stock Performance Updates - Newser
Will earnings trigger a reversal in SCYNEXIS Inc.Weekly Profit Analysis & Long-Term Safe Investment Plans - Newser
Price action breakdown for SCYNEXIS Inc.Trade Risk Assessment & Fast Gain Stock Tips - Newser
Does SCYNEXIS Inc. have pricing power2025 Winners & Losers & Free Expert Verified Stock Movement Alerts - Lancaster City Council
Can SCYNEXIS Inc. disrupt its industryJuly 2025 Big Picture & AI Forecasted Stock Moves - Lancaster City Council
Using economic indicators to assess SCYNEXIS Inc. potentialFed Meeting & Weekly Return Optimization Plans - Newser
Why SCYNEXIS Inc. stock attracts strong analyst attentionWeekly Market Report & Reliable Price Breakout Alerts - Newser
Scynexis Inc Stock (SCYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):